A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
By Richard G. Moore, D. Mcmeekin, Amy K. Brown, P. DiSilvestro, M. Miller, W. Allard, W. Gajewski, R. Kurman, Robert C. Bast, Steven J. Skates. Gynecologic Oncology, 2009
895 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Reproductive Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a17e01465006dd72dd14bc6a096f8a79e5ed5806
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Reproductive Medicine
In Surgery
Citations in the corpus
- 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. (2013, methodology): “In 2008, Moore and colleagues identified human epididymis protein 4 as a biomarker for ovarian cancer.(5) Based on these findings, a Risk Of Ovarian Malignancy Algorithm was developed and currently is used to predict the presence of ovarian cancer using a combination of CA 125, human epididymis prot”
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. (2012, background): “…NS NS MMP14 MT1-MMP Kamat et al. 2006 OS StageZ2C3C4 160020_at 1 NS NS 202828_s_at 1 NS NS 202827_s_at 2 NS NS 217279_x_at 3 NS NS WFDC2 (HE4) Epididymis protein 4 Huhtinen et al. 2009, Moore et al. 2009, 2010 PFS All patients 203892_at 1 NS NS SERPINB5 Maspin Secord et al. 2006 PFS DebulkZsubopt.”
- Calibration: the Achilles heel of predictive analytics (2019, methodology): “The concepts explained in this section are illustrated in Additional 1, with the validation of the Risk of Ovarian Malignancy Algorithm (ROMA) for the diagnosis of ovarian malignancy in women with an ovarian tumor selected for surgical removal [28]; further details can be found elsewhere [1, 4, 29].”